Eli Lilly to invest $3bn in China in anticipation of orforglipron approval

Eli Lilly is continuing its global investment drive to ensure it can meet future demand for its highly anticipated oral weight loss drug orforglipron, outlaying $3bn to expand its supply chain capacity in China. Announcing the 10-year investment on WeChat, Lilly also revealed it submitted an application for orforglipron for the treatment of type 2 diabetes and obesity to China’s National Medical Products Administration (NMPA) at the end of 2025. This investment will occur via a building out of Lilly’s p ...